课题基金 / 基金详情

Analysis of allergic rhinitis by nano level and development of novel therapy

Analysis of allergic rhinitis by nano level and development of novel therapy
纳米级过敏性鼻炎分析及新疗法开发
批准号:
17390458
负责人:
FUJIEDA Shigeharu
金额:
$10.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007

项目摘要

项目成果

FUJIEDA Shigeharu的其他基金

相似基金

相关文献

中文摘要
翻译
我们认为成纤维细胞在免疫系统中不是被动的参与者。与poly(I:C)孵育增强人鼻成纤维细胞分泌RANTES和IL-8。而Eotaxin、IL-1β、TNF-α、IFNα、IFNγ和IL-12均不分泌。JNK抑制剂SP 600125和PI 3激酶抑制剂LY 294002显著阻断poly(I:C)诱导的RANTES和IL-8的分泌,而p38 MAP激酶抑制剂SB 203580抑制poly(I:C)诱导的IL-8的分泌,但不抑制RANTES。IL-4产生的Eotaxin通过PI 3-激酶途径与鼻成纤维细胞中SOCS 5的表达相关。用poly(I:C)诱导产生B淋巴细胞刺激蛋白(BLyS)。BLyS诱导IgE类别转换。浆细胞样树突状细胞(Plasmacytoid dendritic cells,pDC)通过连接TLR 9非甲基化的CpG基序产生大量IFNα。CpG DNA增强NF-κ B亚基p65/p50的活性,其与p38 MAPK协同作用以独立于I型IFN信号的方式上调IRF-7、CXCL 10和CCL 3的表达。I型IFN以NF-κ B非依赖性方式诱导IRF-7的表达,但不诱导IFNα的表达。在NF-κ B/p38 MAPK抑制剂存在下,CpG DNA能使I型IFN处理的pDC表达IFNα,氯喹消除了这种作用。在CpG DNA的作用下,组成型和新表达的IRF-7不依赖于NF-κ B/p38 MAPK而移动到细胞核。我们发现SLIT后血清中有8种蛋白质增加。蛋白质的量与临床结果相关。在接受SLIT的患者中,在48,000个转录物中,32个基因的表达在PBMC中增加。
英文摘要
We proposed that fibroblasts are not passive players in the immune system. Incubation with poly(I:C) enhanced the secretion of RANTES and IL-8 from human nasal fibroblasts. However, eotaxin, IL-1β, TNF-α, IFNα, IFNγ and IL-12 were not secreted. The JNK inhibitor SP600125 and PI3-kinase inhibitor LY294002 significantly blocked the poly(I:C)-induced release RANTES and IL-8, whereas the p38 MAP kinase inhibitor SB203580 suppressed poly(I:C)-induced secretion of IL-8, but not RANTES. Eotaxin production by IL-4 is correlated with expression of SOCS5 in nasal fibroblast via PI3-kinase pathway. B lymphocyte stimulator protein (BLyS) was induced by poly(I:C). BLyS induced IgE class switching. Secretion of BLyS is associated with Rho, Syk, Vav, c-Src, TRAF6, p-Selectin.Plasmacytoid dendritic cells (pDC) produce a large amount of IFNα, through the ligation of TLR9 unmethylated CpG motifs. CpG DNA enhanced the NF-KB subunits p65/p50 activity, which collaborated with p38 MAPK to up-regulate the expression of IRF-7, CXCL10 and CCL3 in a manner independent of type I IFN signaling. Type I IFN induced the expression of IRF-7, but not of IFNα, in a NF-KB -independent way. CpG DNA enabled the type I IFN-treated pDC to express IFNα in the presence of NF-KB/p38 MAPK inhibitor, and chloroquine abrogated this effect. With CpG DNA, IRF-7, both constitutively and newly expressed, moved to the nuclei independent of NF-KB/p38 MAPK.Sublingeal immunotherapy (SLIT) was performed for seasonal allergic rhinitis in Japan. We found 8 proteins that increased in serum after SLIT. The amount of proteins is correlated with clinical outcome. Of 48,000 transcripts, 32-gene expression is increased in PBMC in patients received with SLIT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
DOI: --
发表时间: 2007
期刊: アレルギーの臨床 27
影响因子: --
作者: [山田武千代, 高橋昇, 藤枝重治]
通讯作者: 藤枝重治
Roles of protein tyrosine kinese Syk in nasal polyps.
蛋白酪氨酸激酶 Syk 在鼻息肉中的作用。
DOI: --
发表时间: 2005
期刊: Clin Exp All Rev. 5
影响因子: --
作者: [Yamada T, Takahashi N, Sunaga H, Narita N, Yamamoto H., Fujieda S.]
通讯作者: Fujieda S.
プロテオーム解析による花粉症関連たんぱく質の同定
通过蛋白质组分析鉴定花粉症相关蛋白质
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [牧野友香, 高橋昇, 大澤陽子, 小島章弘, 山田武千代, 目野浩二, 鈴木英昭, 内田和彦, 有波忠雄, 野口恵美子, 藤枝重治]
通讯作者: 藤枝重治
スギ花粉症に対する舌下免疫療法の有効性についての検討(平成19年度版)
舌下免疫疗法治疗雪松花粉病的有效性研究(2007年版)
DOI: --
发表时间: 2007
期刊:
影响因子: --
作者: [高橋昇, 大澤陽子, 藤枝重治]
通讯作者: 藤枝重治
共 15 条
    Prevent and therapeutic strategy bycombination of microarray and proteomics for seasonal allergic rhinitis caused by Japanese cedar pollen.
    • 批准号:
      23390397
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.23万
    • 财政年份:
      2011
    • 负责人:
      FUJIEDA Shigeharu
    • 依托单位:
    New strategy for seasonal allergic rhinitis by exosomes
    • 批准号:
      22659306
    • 项目类别:
      Grant-in-Aid for Challenging Exploratory Research
    • 资助金额:
      $2.01万
    • 财政年份:
      2010
    • 负责人:
      FUJIEDA Shigeharu
    • 依托单位:
    The development of a new therapeutic moleculefor Japanese cedar pollinosis by proteomics analysis in the serum of patients treated with sublingual immunotherapy
    • 批准号:
      20390441
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.65万
    • 财政年份:
      2008
    • 负责人:
      FUJIEDA Shigeharu
    • 依托单位:
    Establishment of gene therapy for the regulation of IgE and Chemokine production in patients with nasal allergy
    • 批准号:
      13470359
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.09万
    • 财政年份:
      2001
    • 负责人:
      FUJIEDA Shigeharu
    • 依托单位:
    国内基金
    去泛素化酶USP13稳定SOCS5调节自噬促进胶质母细胞瘤中的替莫唑胺耐药的机制研究
    m6A修饰调控的miR-32-5p靶向Socs5促进巨噬细胞M1极化诱发UC
    • 批准号:
      2023JJ30537
    • 项目类别:
      省市级项目
    • 资助金额:
      --
    • 批准年份:
      2023
    • 负责人:
      陈玲
    • 依托单位:
    miRNA-369-3p/SOCS5/mTOR轴调控肥大细胞自噬在MRSA肺炎中的作用及机制研究
    • 批准号:
      82000005
    • 项目类别:
      青年科学基金项目
    • 资助金额:
      24.0万元
    • 批准年份:
      2020
    • 负责人:
      刘超
    • 依托单位: